Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

Sponsor
Beth Israel Deaconess Medical Center (Other)
Overall Status
Suspended
CT.gov ID
NCT03736421
Collaborator
Baxter Healthcare Corporation (Industry)
280
3
28.7
93.3
3.3

Study Details

Study Description

Brief Summary

The overall goal of this multicenter project is to characterize the expected normal range of Peripheral IntraVenous Volume Analysis (PIVA) values during a euvolemic state, and how those ranges may be altered by comorbidities; the relationship between PIVA and intravenous volume administration during resuscitation of infected patients with presumed hypovolemia; and, the relationship between PIVA and volume decreases during diuresis in acute heart failure patients with hypervolemia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Peripheral Intravenous Analysis (PIVA)
  • Procedure: Non-invasive fluid response measure
  • Diagnostic Test: Passive leg raise (PLR)

Detailed Description

The determination of volume status remains a clinical challenge in medicine. Patients may develop hypovolemia (too little fluids in the vascular space) due to conditions such as hemorrhage, dehydration, or infection with vascular leak. Alternatively, patients may become hypervolemic (too much fluids in the vascular space), due to conditions such as heart failure, renal failure, or iatragenic over-resuscitation all of which overwhelm the kidney's ability to regulate intravascular volume status. In clinical practice, clinicians strive to return patients to euvolemia (the "right" volume status) through the administration of intravenous fluids or diuretics which remove fluids to achieve homeostasis. While there are a number of proposed clinical exam findings (e.g. dry mucous membranes or skin turgor), measurements (e.g. central venous pressure), or laboratory tests (e.g. blood urea nitrogen), none are precise or universally accepted as reliable methodologies to assess volume status.

The goal of this study is to perform a prospective observational study on three distinct cohorts during ED presentation to assess the variability and performance of PIVA in tracking volume status.

Study Design

Study Type:
Observational
Anticipated Enrollment :
280 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients
Actual Study Start Date :
Nov 10, 2018
Anticipated Primary Completion Date :
Apr 1, 2021
Anticipated Study Completion Date :
Apr 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Control Cohort

This cohort is recruited to help to define what a "normal" PIVA value should be during a state of presumed euvolemia.

Procedure: Peripheral Intravenous Analysis (PIVA)
Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
Other Names:
  • PIVA
  • Diagnostic Test: Passive leg raise (PLR)
    Test to predict cardiac output and fluid responsiveness
    Other Names:
  • PLR
  • Infection Cohort

    This cohort are subjects with suspected infection, enriched to contain sepsis patients.

    Procedure: Peripheral Intravenous Analysis (PIVA)
    Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
    Other Names:
  • PIVA
  • Procedure: Non-invasive fluid response measure
    To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.

    Diagnostic Test: Passive leg raise (PLR)
    Test to predict cardiac output and fluid responsiveness
    Other Names:
  • PLR
  • Acute Heart Failure

    This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.

    Procedure: Peripheral Intravenous Analysis (PIVA)
    Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
    Other Names:
  • PIVA
  • Procedure: Non-invasive fluid response measure
    To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.

    Diagnostic Test: Passive leg raise (PLR)
    Test to predict cardiac output and fluid responsiveness
    Other Names:
  • PLR
  • Outcome Measures

    Primary Outcome Measures

    1. Association between PIVA measurement and fluid status (net gain vs net loss) [Baseline to 6 hours for euvolemic and hypovolemic cohort, and baseline to 72 hours for hypervolemic cohort]

      Change in fluid status over the first 6 hours as measured by weight and urine output and pressure status from the Edwards transducer

    Secondary Outcome Measures

    1. Response to Passive leg raise [For the euvolemic cohort, baseline to 2 hours; For hypovolemic, cohort baseline to 6 hours; for the hypervolemic cohort, baseline up to 72 hours]

      Compute the change in PIVA measurement between before and after the passive leg raise challenge within each cohort

    2. Association between PIVA and non-invasive monitoring responsiveness to passive leg raise [Baseline up to 72 hours]

      Compare change in PIVA measurements to non-invasive monitoring measurements before and after passive leg raise and before and after fluid boluses

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Control Cohort (Presumed Euvolemia)

    Inclusion Criteria:
    • Age > 18 years old

    • Assessed as "euvolemic" by treating physician

    Exclusion Criteria:
    • History of any type of decreased oral intake or volume loss (e.g. diarrhea, vomiting, etc)

    • History of a fever

    • History of bleeding

    • Any acute illness expected to alter volume

    • Known or suspected pregnancy

    • Active irregular heart rhythm

    • In the opinion of the treating physician, no anticipated intravenous fluid administration

    • History of chronic or end stage renal disease

    • Liver failure

    • History of Acute heart failure

    • Presence of abnormal vital signs (90 < HR < 60; 180 < SBP < 110, respiratory rate > 20, pulse ox < 92% or need for supplemental oxygen, 99.0 < temperature < 96).

    2 additional group will be included in this euvolemic group

    • Non-elderly patients (age < 50 year) without any comorbid illnesses and

    • Age >65

    • Diabetes on medications

    • Hypertension on medications

    • Vascular disease defined by history of peripheral vascular disease, stroke, MI

    Note: patients that receive >250 cc of IVF will be excluded from analysis.

    Infection Cohort (Presumed Hypovolemia)

    Inclusion Criteria:
    • Age > 18 years old

    • An accessible intravenous catheter is in place

    • Known or suspected infection as assessed by the clinical team

    • Intention to admit to the hospital

    • Anticipated administration of intravenous fluids per clinical team

    Exclusion Criteria:
    • Clinical exam consistent with volume overload

    • Known or suspected pregnancy

    • Patients with a history of chronic renal insufficiency or end-stage renal disease

    • Patients with a history of acute heart failure

    Acute Heart Failure (Hypervolemic cohort)

    Inclusion Criteria:
    • Age > 17 years old

    • An accessible intravenous catheter is in place

    • Primary clinical diagnosis of CHF

    • Meet 2 of the three criterion:

    • X-ray diagnosis

    • Elevated bnp from known baseline

    • Clinical diagnosis

    • Received or intent to administer a diuretic agent

    • Intent to admit to the hospital for anticipated > 24 hour period

    Exclusion Criteria:
    • History of any type of decreased oral intake or volume loss (e.g. diarrhea, vomiting, etc)

    • History of a fever

    • History of bleeding

    • Known or suspected pregnancy

    • Active irregular heart rhythm

    • History of dialysis dependent end stage renal disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Beth Israel Medical Center Boston Massachusetts United States 02215
    2 St. Vincent Hospital Worcester Massachusetts United States 01608
    3 University of Washington Seattle Washington United States 98104

    Sponsors and Collaborators

    • Beth Israel Deaconess Medical Center
    • Baxter Healthcare Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Beth Israel Deaconess Medical Center
    ClinicalTrials.gov Identifier:
    NCT03736421
    Other Study ID Numbers:
    • 2018P000494
    First Posted:
    Nov 9, 2018
    Last Update Posted:
    Jun 23, 2020
    Last Verified:
    Jun 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 23, 2020